Braun Stacey Associates Inc. Sells 34,949 Shares of Amgen Inc. $AMGN

Braun Stacey Associates Inc. cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 88.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,500 shares of the medical research company’s stock after selling 34,949 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Amgen were worth $1,270,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. State of Wyoming acquired a new position in Amgen in the first quarter valued at approximately $212,000. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Amgen by 5.5% during the 1st quarter. Federation des caisses Desjardins du Quebec now owns 29,650 shares of the medical research company’s stock worth $9,238,000 after buying an additional 1,538 shares in the last quarter. Aprio Wealth Management LLC grew its position in shares of Amgen by 11.2% during the 1st quarter. Aprio Wealth Management LLC now owns 1,383 shares of the medical research company’s stock worth $431,000 after buying an additional 139 shares during the period. Finally, AQR Capital Management LLC increased its stake in shares of Amgen by 103.0% in the 1st quarter. AQR Capital Management LLC now owns 91,493 shares of the medical research company’s stock valued at $28,321,000 after acquiring an additional 46,417 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In related news, SVP Rachna Khosla sold 890 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by corporate insiders.

Amgen Trading Down 0.4%

AMGN opened at $327.31 on Friday. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. Amgen Inc. has a fifty-two week low of $257.05 and a fifty-two week high of $346.38. The firm has a market capitalization of $176.25 billion, a PE ratio of 25.29, a P/E/G ratio of 3.04 and a beta of 0.45. The company’s 50-day moving average is $325.36 and its 200 day moving average is $302.57.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 3.1%. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is currently 73.57%.

Analysts Set New Price Targets

Several brokerages recently issued reports on AMGN. Bank of America increased their target price on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. BMO Capital Markets increased their price objective on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. DZ Bank raised their target price on Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. Citigroup upped their price target on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 24th. Finally, Daiwa Capital Markets increased their price target on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $335.35.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.